Mineralys Therapeutics Inc (MLYS)

06:08 AM

What drives Mineralys Therapeutics Inc. stock priceTriple-digit return opportunities - Autocar Professional

06:08 AM

04:47 AM

What analysts say about Mineralys Therapeutics Inc. stockRecord-breaking gains - Autocar Professional

04:47 AM

Jul 22, 2025

Mineralys Therapeutics Inc. Stock Analysis and ForecastMarket-crushing profits - jammulinksnews.com

Jul 22, 2025

Jul 20, 2025

Is Mineralys Therapeutics Inc. a good long term investmentFree Stock Selection - jammulinksnews.com

Jul 20, 2025

Jul 17, 2025

Mineralys Therapeutics Reports Positive Phase 2 Trial Results for Lorundrostat in Hypertension and CKD - MSN

Jul 17, 2025

Jul 17, 2025

(MLYS) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jul 17, 2025

Jul 15, 2025

Mineralys Therapeutics CFO Adam Levy sells $155k in stock By Investing.com - Investing.com South Africa

Jul 15, 2025

Jul 15, 2025

Mineralys Therapeutics CEO Congleton sells $230k in shares By Investing.com - Investing.com South Africa

Jul 15, 2025

Jul 15, 2025

MLYS SEC FilingsMineralys Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 15, 2025

Jul 15, 2025

Mineralys Therapeutics, Inc. (MLYS) Receives a Hold from Jefferies - The Globe and Mail

Jul 15, 2025

Jul 14, 2025

Jefferies Initiates Mineralys Therapeutics(MLYS.US) With Hold Rating, Announces Target Price $15 - 富途牛牛

Jul 14, 2025

Jul 14, 2025

Promising Investment Opportunity in Mineralys Therapeutics Driven by Lorundrostat’s Clinical Success - TipRanks

Jul 14, 2025

Jul 14, 2025

Jefferies maintains Hold rating on Mineralys stock amid AstraZeneca data By Investing.com - Investing.com South Africa

Jul 14, 2025

Jul 14, 2025

Jefferies maintains Hold rating on Mineralys stock amid AstraZeneca data - Investing.com Australia

Jul 14, 2025

Jul 14, 2025

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat - insights.citeline.com

Jul 14, 2025

Jul 03, 2025

Mineralys Therapeutics: Navigating Cash Burn and Clinical Triumphs in a $200B Market - AInvest

Jul 03, 2025

Jul 03, 2025

Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment - MSN

Jul 03, 2025

Jul 02, 2025

Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat - MSN

Jul 02, 2025

Jul 02, 2025

Here's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation - Yahoo.co

Jul 02, 2025

Jul 02, 2025

Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement - MyChesCo

Jul 02, 2025

Jun 30, 2025

Mineralys reports positive phase 3 results for hypertension drug By Investing.com - Investing.com Canada

Jun 30, 2025

Jun 30, 2025

Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell 2000 Value Index - MarketScreener

Jun 30, 2025

Jun 30, 2025

Mineralys reports positive phase 3 results for hypertension drug - Investing.com

Jun 30, 2025

Jun 26, 2025

(MLYS) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 26, 2025

Jun 25, 2025

Is Mineralys Therapeutics, Inc. technically bullish or bearish? - MarketsMojo

Jun 25, 2025

Jun 24, 2025

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca - insights.citeline.com

Jun 24, 2025

Jun 23, 2025

Lorundrostat Shows Clinically Meaningful Outcomes in Patients With CKD and Hypertension - Pharmacy Times

Jun 23, 2025

Jun 18, 2025

Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial - Investing.com Canada

Jun 18, 2025

Jun 18, 2025

Mineralys enhances lorundrostat data package ahead of planned NDA - The Pharma Letter

Jun 18, 2025

Jun 18, 2025

Mineralys Therapeutics (MLYS): Analyst Reiterates Buy Rating and Price Target | MLYS Stock News - GuruFocus

Jun 18, 2025